inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 \& 7) (and/or) 5. patients receiving hormonal therapy for cancer (and/or) 6. patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get covid pneumonia in the interim (incl. criteria 11) 8. men and women aged ≥ 25 - 80 (included) years of age 9. hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 10. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4l per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 11. confirmed infection with covid-19 by any acceptable test available/utilized at each site 12. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 \& 7) (and/or) 5. patients receiving hormonal therapy for cancer (and/or) 6. patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get covid pneumonia in the interim (incl. criteria 11) 8. men and women aged ≥ 25 - 80 (included) years of age 9. hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 10. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4l per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 11. confirmed infection with covid-19 by any acceptable test available/utilized at each site 12. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 & 7) (and/or) patients receiving hormonal therapy for cancer (and/or) patients who have undergone surgery or radiotherapy for cancer within the past 6 months patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get covid pneumonia in the interim (incl. criteria 11) men and women aged ≥ 25 - 80 (included) years of age hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure confirmed infection with covid-19 by any acceptable test available/utilized at each site willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 & 7) (and/or) patients receiving hormonal therapy for cancer (and/or) patients who have undergone surgery or radiotherapy for cancer within the past 6 months patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get covid pneumonia in the interim (incl. criteria 11) men and women aged ≥ 25 - 80 (included) years of age hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure confirmed infection with covid-19 by any acceptable test available/utilized at each site willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 & 7) (and/or) 5. patients receiving hormonal therapy for cancer (and/or) 6. patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get covid pneumonia in the interim (incl. criteria 11) 8. men and women aged ≥ 25 - 80 (included) years of age 9. hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 10. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 11. confirmed infection with covid-19 by any acceptable test available/utilized at each site 12. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 & 7) (and/or) 5. patients receiving hormonal therapy for cancer (and/or) 6. patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get covid pneumonia in the interim (incl. criteria 11) 8. men and women aged ≥ 25 - 80 (included) years of age 9. hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 10. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 11. confirmed infection with covid-19 by any acceptable test available/utilized at each site 12. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 & 7) (and/or) 5. patients receiving hormonal therapy for cancer (and/or) 6. patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. men and women aged ≥ 25 - 80 (included) years of age 8. hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 9. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 10. confirmed infection with covid-19 by any acceptable test available/utilized at each site 11. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. patients who received car-t cell therapy within the past 1 year (but not within last 30 days- see also exclusion criteria number 6 & 7) (and/or) 5. patients receiving hormonal therapy for cancer (and/or) 6. patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. men and women aged ≥ 25 - 80 (included) years of age 8. hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 9. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 10. confirmed infection with covid-19 by any acceptable test available/utilized at each site 11. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient with recent or ongoing cancer treatment 3. men and women aged ≥ 25 - 80 (included) years of age 4. hospitalized patients with two absolute lymphocyte count (alc) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following hospitalization. from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 5. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 6. confirmed infection with covid-19 by any acceptable test available/utilized at each site 7. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure 8. private insurance with medical insurance or government support

inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. patient with recent or ongoing cancer treatment 3. men and women aged ≥ 25 - 80 (included) years of age 4. hospitalized patients with two absolute lymphocyte count (alc) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following hospitalization. from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status. 5. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure 6. confirmed infection with covid-19 by any acceptable test available/utilized at each site 7. willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure 8. private insurance with medical insurance or government support